Condition: Advanced Solid Tumor · Sponsor: TaiRx, Inc.
The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that directly contains SN38 instead of Irinotecan. A series of biology and animal studies have demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects compared to Irinotecan.
This description comes directly from the study's public registry record.
Yen-Ling Chen, Ph.D. · +886226535007 · yenlingchen@trx.com.tw
Always discuss trial participation with your own doctor first.
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| National Cheng-Kung University Hospital | Tainan, Taiwan | Recruiting |
| Taipei Medical University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06143774